Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Approved For Marketing No phase listed Expanded access

Afatinib Expanded Access Program

ClinicalTrials.gov ID: NCT01649284

Public ClinicalTrials.gov record NCT01649284. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 10, 2026, 12:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

LUX-Lung EAP US; An Open Label Expanded Access Program of Afatinib (BIBW 2992) for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open-label, multi-center, single-arm trial, designed to provide early access to afatinib and to provide additional information on the safety and efficacy of afatinib in advanced NSCLC patients who harbor an EGFR mutation.

Study identification

NCT ID
NCT01649284
Recruitment status
Approved For Marketing
Study type
Expanded access
Phase
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
Not listed

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2012
Primary completion
Feb 28, 2014
Completion
Feb 28, 2014
Last update posted
Nov 29, 2016

2012 – 2014

United States locations

U.S. sites
66
U.S. states
33
U.S. cities
62
Facility City State ZIP Site status
1200.45.004 Boehringer Ingelheim Investigational Site Mobile Alabama
1200.45.116 Boehringer Ingelheim Investigational Site Goodyear Arizona
1200.45.057 Boehringer Ingelheim Investigational Site Hot Springs Arkansas
1200.45.078 Boehringer Ingelheim Investigational Site Anaheim California
1200.45.114 Boehringer Ingelheim Investigational Site Burbank California
1200.45.123 Boehringer Ingelheim Investigational Site Glendale California
1200.45.115 Boehringer Ingelheim Investigational Site Lakewood California
1200.45.117 Boehringer Ingelheim Investigational Site Long Beach California
1200.45.102 Boehringer Ingelheim Investigational Site Monterey California
1200.45.091 Boehringer Ingelheim Investigational Site Pleasant Hill California
1200.45.098 Boehringer Ingelheim Investigational Site Pleasant Hill California
1200.45.006 Boehringer Ingelheim Investigational Site Ranco Cucamonga California
1200.45.003 Boehringer Ingelheim Investigational Site Southington Connecticut
1200.45.007 Boehringer Ingelheim Investigational Site Stamford Connecticut
1200.45.026 Boehringer Ingelheim Investigational Site Hollywood Florida
1200.45.097 Boehringer Ingelheim Investigational Site Hollywood Florida
1200.45.017 Boehringer Ingelheim Investigational Site Jacksonville Florida
1200.45.058 Boehringer Ingelheim Investigational Site Jacksonville Florida
1200.45.016 Boehringer Ingelheim Investigational Site Lakeland Florida
1200.45.103 Boehringer Ingelheim Investigational Site Miami Beach Florida
1200.45.037 Boehringer Ingelheim Investigational Site Orlando Florida
1200.45.056 Boehringer Ingelheim Investigational Site Port Saint Lucie Florida
1200.45.119 Boehringer Ingelheim Investigational Site Titusville Florida
1200.45.095 Boehringer Ingelheim Investigational Site Alpharetta Georgia
1200.45.029 Boehringer Ingelheim Investigational Site Athens Georgia
1200.45.042 Boehringer Ingelheim Investigational Site Macon Georgia
1200.45.121 Boehringer Ingelheim Investigational Site Valdosta Georgia
1200.45.024 Boehringer Ingelheim Investigational Site Decatur Illinois
1200.45.009 Boehringer Ingelheim Investigational Site Evanston Illinois
1200.45.099 Boehringer Ingelheim Investigational Site Peoria Illinois
1200.45.040 Boehringer Ingelheim Investigational Site Waterloo Iowa
1200.45.041 Boehringer Ingelheim Investigational Site Wichita Kansas
1200.45.083 Boehringer Ingelheim Investigational Site Marrero Louisiana
1200.45.087 Boehringer Ingelheim Investigational Site Metairie Louisiana
1200.45.019 Boehringer Ingelheim Investigational Site Columbia Maryland
1200.45.039 Boehringer Ingelheim Investigational Site Rockville Maryland
1200.45.053 Boehringer Ingelheim Investigational Site Ann Arbor Michigan
1200.45.046 Boehringer Ingelheim Investigational Site Detroit Michigan
1200.45.100 Boehringer Ingelheim Investigational Site Jackson Mississippi
1200.45.067 Boehringer Ingelheim Investigational Site St Louis Missouri
1200.45.071 Boehringer Ingelheim Investigational Site Billings Montana
1200.45.021 Boehringer Ingelheim Investigational Site Omaha Nebraska
1200.45.066 Boehringer Ingelheim Investigational Site Freehold New Jersey
1200.45.105 Boehringer Ingelheim Investigational Site Albuquerque New Mexico
1200.45.080 Boehringer Ingelheim Investigational Site Brooklyn New York
1200.45.068 Boehringer Ingelheim Investigational Site Fresh Meadows New York
1200.45.051 Boehringer Ingelheim Investigational Site New York New York
1200.45.092 Boehringer Ingelheim Investigational Site New York New York
1200.45.001 Boehringer Ingelheim Investigational Site Charlotte North Carolina
1200.45.086 Boehringer Ingelheim Investigational Site Bismarck North Dakota
1200.45.048 Boehringer Ingelheim Investigational Site Minot North Dakota
1200.45.090 Boehringer Ingelheim Investigational Site Canton Ohio
1200.45.005 Boehringer Ingelheim Investigational Site Columbus Ohio
1200.45.089 Boehringer Ingelheim Investigational Site Tulsa Oklahoma
1200.45.094 Boehringer Ingelheim Investigational Site Portland Oregon
1200.45.020 Boehringer Ingelheim Investigational Site Hershey Pennsylvania
1200.45.096 Boehringer Ingelheim Investigational Site Johnstown Pennsylvania
1200.45.060 Boehringer Ingelheim Investigational Site Philadelphia Pennsylvania
1200.45.085 Boehringer Ingelheim Investigational Site Pottstown Pennsylvania
1200.45.120 Boehringer Ingelheim Investigational Site Rapid City South Dakota
1200.45.049 Boehringer Ingelheim Investigational Site Cookeville Tennessee
1200.45.113 Boehringer Ingelheim Investigational Site El Paso Texas
1200.45.045 Boehringer Ingelheim Investigational Site Fairfax Virginia
1200.45.076 Boehringer Ingelheim Investigational Site Seattle Washington
1200.45.093 Boehringer Ingelheim Investigational Site Charleston West Virginia
1200.45.125 Boehringer Ingelheim Investigational Site Wausau Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01649284, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 29, 2016 · Synced Sep 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01649284 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →